US equities |
MU $1,069.38 ▼-1.71% NVDA $236.77 ▼-0.29% PLTR $199.53 ▲+2.79% SNDK $1,648.62 ▼-2.59% AMD $637.00 ▼-1.37% INTC $109.58 ▼-3.13% META $721.46 ▲+0.02% SPCX $164.73 ▼-1.71%
FinancialContent

Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

0.4260 +0.0060 (+1.43%)
Delayed Quote Updated: 10:37 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Estrella Immunopharma, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. Estrella Immunopharma... 
Via Benzinga
News headline image
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
From Estrella Immunopharma, Inc.
Via Business Wire
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
From Estrella Immunopharma, Inc.
Via Business Wire
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
From Estrella Immunopharma, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: top gainers and losers ↗
Via Chartmill
News headline image
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
From Estrella Immunopharma, Inc.
Via Business Wire
BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
Via Investor Brand Network
News headline image
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Tuesday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Monday? ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
From Estrella Immunopharma, Inc.
Via Business Wire
News headline image
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
From Estrella Immunopharma, Inc.
Via Business Wire
< Previous 1 2 Next >